Almac expands global biologics testing capabilities

The $0.68m instrumentation investment will allow the company to expand its mass spectrometry offering

Almac Sciences has announced an additional expansion of its biologics testing laboratory with an investment in mass spectrometry equipment.

A high-resolution mass spectrometer has been installed at the company’s global headquarters in Northern Ireland, and will support its biologics offering for the analysis of peptides, proteins, glycoproteins and antibody products. This adds to existing industry support at its biologic testing laboratory based in Athlone, Ireland, announced three months ago, which supports QC release and characterisation of biologics.

The investment in a Thermo Orbitrap LC-MS instrument increases the company’s capabilities in solving biologic analytical challenges. The instrument is capable of offering an analysis package amino acid sequencing, peptide mapping, disulfide bridge analysis using MS and MS/MS, glycosylation analysis, identification of post-translational modifications e.g. acetylation, phosphorylation in addition to biomarker discovery.

The company will now offer an extended range of mass spectrometry services including the quantitation of genotoxic impurities, structure elucidation, isotopic purity determinations and high-resolution mass spectrometry of both large and small molecules.

John Robson, VP Analytical Services, Almac Sciences said: “This new mass spectrometer reinforces Almac’s vision of delivering the best for our customers and substantially enhances the level and depth of services we provide.”

John Malone, Analytical Manager, said: “We are delighted with this vital investment – whilst customer focus is always our priority, we are confident that the enhanced service offering will benefit our clients further.”

Companies